As doubts con­tin­ue to fes­ter, In­ovio gets an­oth­er shove as Roche ex­its col­lab­o­ra­tion

Three years af­ter Roche signed up for a $422 mil­lion col­lab­o­ra­tion pact with In­ovio $INO on a pair of its ear­ly-stage de­vel­op­ment pro­grams, the phar­ma gi­ant is bow­ing out of the last re­main­ing ef­fort in the part­ner­ship. In­ovio says that it will take over the Phase I study for the he­pati­tis B vac­cine INO-1800, which is now fi­nal­ly en­rolling pa­tients.

Roche took con­sid­er­ably less time on INO-5150, its can­cer vac­cine. The com­pa­ny bowed out of that pro­gram in 2014. At the time, In­ovio had said it was start­ing a Phase I on 5150 in 2015. But ac­cord­ing to its pipeline chart, that’s where it still sits to­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.